BioFlyte: Funding, Investors & Team (Oct 2026)
BioFlyte is commercializing a revolutionary new class of fieldable aerosol mass spectrometers and complementary products for protection from biological and low-volatility chemical threats. Our instruments identify microbes including spores, vegetative bacteria, and viruses, bio-toxins, opioids, and other airborne threats to our safety and security. Our products are designed to autonomously sample ambient air, for example, in critical infrastructure, but can also accept liquid or powder samples manually.
BioFlyte has raised $12.8M across 3 funding rounds on record, the most recent a Series B of $5.4M announced in Aug 2023.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BioFlyte Company Profile and Key Stats
Latest funding round on record: Aug 2023.
BioFlyte Funding Rounds
BioFlyte raised $1.3M in an undisclosed round announced in Jun 2020.
1.8 years later, a Series A of $6.1M was announced in Apr 2022.
1.3 years later, a Series B of $5.4M was announced in Aug 2023.
BioFlyte Founders and Leadership Team
No contact details are on record for this team yet.
BioFlyte Funding Compared to Other Biotechnology Startups
BioFlyte's latest round of $5.4M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BioFlyte in Biotechnology and Albuquerque
Companies Similar to BioFlyte
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
BioFlyte Funding FAQs
What does BioFlyte do?
BioFlyte is commercializing a revolutionary new class of fieldable aerosol mass spectrometers and complementary products for protection from biological and low-volatility chemical threats. Our instruments identify microbes including spores, vegetative bacteria, and viruses, bio-toxins, opioids, and other airborne threats to our safety and security. Our products are designed to autonomously sample ambient air, for example, in critical infrastructure, but can also accept liquid or powder samples manually.
How much funding has BioFlyte raised?
BioFlyte has raised $12.8M across 3 rounds on record. The most recent is a Series B of $5.4M announced in Aug 2023.
When did BioFlyte last raise funding?
BioFlyte's most recent funding round on record is a Series B of $5.4M, announced in Aug 2023.
Who is the CEO of BioFlyte?
Charles Call is listed as CEO at BioFlyte.
Where is BioFlyte headquartered?
BioFlyte is based in Albuquerque, New Mexico, United States.
How many employees does BioFlyte have?
BioFlyte is in the 1-10 employee band.
How does BioFlyte's funding compare to other Biotechnology startups?
BioFlyte's latest round of $5.4M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's BioFlyte Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BioFlyte is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.